Cramer Rosenthal Mcglynn LLC raised its stake in Allergan plc (NYSE:AGN) by 42.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 605,259 shares of the company’s stock after purchasing an additional 179,489 shares during the period. Allergan accounts for approximately 1.6% of Cramer Rosenthal Mcglynn LLC’s holdings, making the stock its 7th biggest holding. Cramer Rosenthal Mcglynn LLC’s holdings in Allergan were worth $99,008,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Focused Wealth Management Inc grew its position in shares of Allergan by 4,444.4% during the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after buying an additional 800 shares during the last quarter. BB&T Investment Services Inc. grew its position in shares of Allergan by 1,308.2% during the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after buying an additional 641 shares during the last quarter. Acropolis Investment Management LLC bought a new stake in shares of Allergan during the 4th quarter valued at about $153,000. Field & Main Bank bought a new stake in shares of Allergan during the 4th quarter valued at about $155,000. Finally, Zions Bancorporation grew its position in shares of Allergan by 1,115.6% during the 3rd quarter. Zions Bancorporation now owns 936 shares of the company’s stock valued at $192,000 after buying an additional 859 shares during the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.
A number of brokerages recently weighed in on AGN. Credit Suisse Group set a $215.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, March 1st. Morgan Stanley lowered their price objective on shares of Allergan from $200.00 to $181.00 and set an “overweight” rating for the company in a research report on Thursday, March 1st. SunTrust Banks began coverage on shares of Allergan in a research report on Friday, February 23rd. They set a “buy” rating and a $200.00 price objective for the company. They noted that the move was a valuation call. Bank of America boosted their price objective on shares of Allergan from $208.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Finally, Leerink Swann boosted their price objective on shares of Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Allergan presently has an average rating of “Buy” and an average price target of $225.03.
Allergan plc (NYSE:AGN) opened at $157.28 on Monday. The company has a market cap of $54,786.71, a PE ratio of -11.72, a price-to-earnings-growth ratio of 1.11 and a beta of 1.29. Allergan plc has a 1 year low of $142.81 and a 1 year high of $256.80. The company has a quick ratio of 1.06, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. The company had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business posted $3.90 EPS. sell-side analysts forecast that Allergan plc will post 15.58 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be paid a $0.72 dividend. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s dividend payout ratio is currently -21.46%.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3256912/cramer-rosenthal-mcglynn-llc-has-99-01-million-stake-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.